129 related articles for article (PubMed ID: 24499082)
21. Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients.
Gonzalez E; Schomberg J; Amin N; Salusky IB; Zaritsky J
Pediatr Nephrol; 2010 Feb; 25(2):373-5. PubMed ID: 19876653
[TBL] [Abstract][Full Text] [Related]
22. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
[TBL] [Abstract][Full Text] [Related]
23. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.
Fan S; Ross C; Mitra S; Kalra P; Heaton J; Hunter J; Plone M; Pritchard N
Nephrol Dial Transplant; 2009 Dec; 24(12):3794-9. PubMed ID: 19666658
[TBL] [Abstract][Full Text] [Related]
24. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
Sun PP; Perianayagam MC; Jaber BL
J Ren Nutr; 2009 Sep; 19(5):432-8. PubMed ID: 19464926
[TBL] [Abstract][Full Text] [Related]
25. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.
Koiwa F; Kazama JJ; Tokumoto A; Onoda N; Kato H; Okada T; Nii-Kono T; Fukagawa M; Shigematsu T;
Ther Apher Dial; 2005 Aug; 9(4):336-9. PubMed ID: 16076378
[TBL] [Abstract][Full Text] [Related]
26. The role of sevelamer carbonate in increasing serum bicarbonate in hyperphosphatemic predialysis patients who have metabolic acidosis.
Bezzaoucha S; Pichette V; Lafrance JP; Bell R; Laurin LP; Vallée M
Int J Clin Pharmacol Ther; 2013 Dec; 51(12):989-90. PubMed ID: 24075095
[No Abstract] [Full Text] [Related]
27. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
[TBL] [Abstract][Full Text] [Related]
28. Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients.
Filiopoulos V; Koutis I; Trompouki S; Hadjiyannakos D; Lazarou D; Vlassopoulos D
Ther Apher Dial; 2011 Feb; 15(1):20-7. PubMed ID: 21272248
[TBL] [Abstract][Full Text] [Related]
29. Determinants of metabolic acidosis among hemodialysis patients.
Soudan K; Ricanati ES; Leon JB; Sehgal AR
Hemodial Int; 2006 Apr; 10(2):209-14. PubMed ID: 16623676
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
Iwasaki Y; Takami H; Tani M; Yamaguchi Y; Goto H; Goto Y; Goto Y; Shigematsu T
Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
Wilkes BM; Reiner D; Kern M; Burke S
Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
[TBL] [Abstract][Full Text] [Related]
32. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
Koiwa F; Onoda N; Kato H; Tokumoto A; Okada T; Fukagawa M; Shigematsu T;
Ther Apher Dial; 2005 Aug; 9(4):340-6. PubMed ID: 16076379
[TBL] [Abstract][Full Text] [Related]
33. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
34. The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
Beaubien-Souligny W; Bezzaoucha S; Pichette V; Lafrance JP; Bell R; Lamarche C; Ouimet D; Vallee M
Int Urol Nephrol; 2015 Jul; 47(7):1165-71. PubMed ID: 25982583
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis.
Thet Z; Win AK; Pedagogos E; Beavis J; Crikis S; Nelson C
BMC Nephrol; 2013 Oct; 14():205. PubMed ID: 24079654
[TBL] [Abstract][Full Text] [Related]
36. Homocysteine and folic acid levels in hemodialysis patients treated with sevelamer hydrochloride.
Goto S; Fujii H; Kim JI; Fukagawa M
Clin Nephrol; 2010 Jun; 73(6):420-5. PubMed ID: 20497753
[TBL] [Abstract][Full Text] [Related]
37. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
[TBL] [Abstract][Full Text] [Related]
38. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Bommer J; Locatelli F; Satayathum S; Keen ML; Goodkin DA; Saito A; Akiba T; Port FK; Young EW
Am J Kidney Dis; 2004 Oct; 44(4):661-71. PubMed ID: 15384017
[TBL] [Abstract][Full Text] [Related]
39. [Multiple peritrochanteric and pubic calcifications in a young woman on hemodialysis with severe renal osteodystrophy successfully treated with sevelamer+cinacalcet+paracalcitol combination therapy].
Bellotti G; Presta P; Panzino T; Capria M; Caglioti A; Riccio M; Bova F; Fuiano L; Fuiano G
G Ital Nefrol; 2009; 26(3):372-6. PubMed ID: 19554535
[TBL] [Abstract][Full Text] [Related]
40. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
Suki WN;
J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
